-
1.发明申请公开(公告)号：US20190048053A1
公开(公告)日：2019-02-14
申请号：US16074086
申请日：2017-02-03
发明人： Varda ROTTER , Moshe OREN , Perry TAL , Shay EIZENBERGER , Avi BEN-SHIMON
摘要： An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
-
公开(公告)号：US20160166582A1
公开(公告)日：2016-06-16
申请号：US15050502
申请日：2016-02-23
发明人： Irina LAVELIN , Varda ROTTER , Moshe OREN , Ami NAVON , Zvi KAM , Benjamin GEIGER
IPC分类号： A61K31/555 , G01N33/50 , C07K14/47 , A61K31/522 , A61K31/47
CPC分类号： A61K31/555 , A61K31/47 , A61K31/52 , A61K31/522 , A61K31/60 , A61K33/34 , C07K14/4746 , C07K2319/40 , C07K2319/60 , C12N9/6421 , C12Y304/25001 , G01N33/5035
摘要： A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.
-
公开(公告)号：US20150297693A1
公开(公告)日：2015-10-22
申请号：US14754835
申请日：2015-06-30
发明人： Johannes HERKEL , Irun R. COHEN , Varda ROTTER , Ansgar W. LOHSE , Neta EREZ , Avishai MIMRAN , Na'aman KAM
IPC分类号： A61K39/00
CPC分类号： A61K39/0008 , A61K38/00 , A61K39/0005 , C07K7/06 , C07K7/08 , C07K14/435
摘要： The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.
摘要翻译： 本发明涉及能够抑制真核细胞中的细胞和免疫应答反应的肽。 本发明提供了利用这些肽治疗人退行性疾病和炎症的组合物和方法。
-
公开(公告)号：US20220251159A1
公开(公告)日：2022-08-11
申请号：US17549369
申请日：2021-12-13
发明人： Varda ROTTER , Moshe OREN , Perry TAL , Shay EIZENBERGER , Avi BEN-SHIMON
摘要： An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
-
公开(公告)号：US20200095282A1
公开(公告)日：2020-03-26
申请号：US16704010
申请日：2019-12-05
发明人： Moshe OREN , Varda ROTTER , Perry TAL
摘要： The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
-
公开(公告)号：US20190315804A1
公开(公告)日：2019-10-17
申请号：US16451081
申请日：2019-06-25
发明人： Moshe OREN , Varda ROTTER , Perry TAL
摘要： The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
-
公开(公告)号：US20230127559A1
公开(公告)日：2023-04-27
申请号：US17911277
申请日：2021-03-15
发明人： Varda ROTTER , Moshe OREN , Perry TAL , Fernando ALBERICIO
摘要： Peptide analogs which are endowed with the property of at least partially reactivating a mutant p53 protein are provided. Also provided are uses thereof in the treatment of diseases associated with mutant p53.
-
公开(公告)号：US20180057533A1
公开(公告)日：2018-03-01
申请号：US15796811
申请日：2017-10-29
发明人： Moshe OREN , Varda ROTTER , Perry TAL
摘要： The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
-
公开(公告)号：US20150366944A1
公开(公告)日：2015-12-24
申请号：US14766151
申请日：2014-02-19
发明人： Varda ROTTER , Naomi GOLDFINGER , Shalom MADAR , Yan STEIN
IPC分类号： A61K38/21 , C12Q1/68 , G01N33/574 , C07K14/565 , C07K14/56
CPC分类号： A61K38/215 , A61K38/212 , C07K14/56 , C07K14/565 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/57496 , G01N2333/4748
摘要： The present invention is directed to cancer therapy, specifically to prognostic and therapeutic compositions and methods, wherein expression of a mutated form of p53 serves as a predictive marker for successful type I interferon (IFN) treatment. The invention also relates to the use of low doses of IFN having reduced clinical toxicity, and enables the use of IFN to prevent tumor formation in susceptible patient populations such as patients carrying p53 germline mutations.
摘要翻译： 本发明涉及癌症治疗，特别涉及预后和治疗组合物和方法，其中突变形式的p53的表达用作成功的I型干扰素（IFN）治疗的预测标记。 本发明还涉及使用具有降低的临床毒性的低剂量IFN，并且能够使用IFN来预防易感患者群体如携带p53种系突变的患者的肿瘤形成。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.025 秒)
